Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

NEXT STORY
Cannabis Science Issues First 2018 Guidance Report; 4/20 Court Date Set For Lawsuit Against San Joaquin County; Revenue Growth Through Acquisitions, Wholesale, and Retail Sales Channels All Multiply
PREV STORY
CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients

Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company ...

author_avatar
NASDAQ Market News

Global Digital Health Market to Surpass $1,045.8 Million, Growing with a CAGR of 33.4% from 2020 to 2027, Post-COVID-19 Turmoil – Exclusive Report [320 pages] by Research Dive

author_avatar
NASDAQ Market News

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

author_avatar
NASDAQ Market News